1. Alzheimer’s Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials

   • Michael S. Rafii

   Leading Article 06 June 2020 Pages: 785 - 794

   

2. Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications

   • Emilio Perucca
   • Meir Bialer

   Leading Article 05 June 2020 Pages: 795 - 800

3. Therapeutic Options for Patients with Refractory Status Epilepticus in Palliative Settings or with a Limitation of Life-Sustaining Therapies: A Systematic Review

   • Laurent M. Willems
   • Sebastian Bauer
   • Adam Strzelczyk

   Systematic Review Open access 23 July 2020 Pages: 801 - 826

   

4. Methadone for Pain Management: A Pharmacotherapeutic Review

   • Denise Kreutzwiser
   • Qutaiba A. Tawfic

   Review Article 20 June 2020 Pages: 827 - 839

   

5. Newer Formulations of Risperidone: Role in the Management of Psychotic Disorders

   • Ivana Clark
   • David Taylor

   Review Article 27 May 2020 Pages: 841 - 852

   

6. A Phase I, Randomized, Single‑Blind, Placebo‑Controlled, Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous and Oral TRV250, a G Protein-Selective Delta Receptor Agonist, in Healthy Subjects

   • Michael J. Fossler
   • Virginia Schmith
   • Mark A. Demitrack

   Original Research Article Open access 16 July 2020 Pages: 853 - 865

   

7. Pharmacokinetics, Safety, and Tolerability of Intravenous Felbinac Trometamol in Healthy Chinese Volunteers: A First-in-Human Single- and Multiple-Dose Escalation Phase I Study with a Randomized, Double-Blind, Placebo-Controlled Design

   • Min Wu
   • Cuiyun Li
   • Yanhua Ding

   Original Research Article 22 July 2020 Pages: 867 - 877